Cancer immunotherapy
Alemany’s & Piulats’s lab

DESCRIPTION

Our main aim is to develop new anticancer treatments based on novel designs of oncolytic adenoviruses, combining them with mesenchymal stem cells and cellular therapies derived from tumor reactive T-lymphocytes against solid tumors.

The Cancer Immunotherapy group, led by Dr Piulats and Dr Alemany, is dedicated to develop new immunotherapies based on oncolytic adenoviruses or advanced therapy medicinal products (ATMPs) to treat the so-called “cold” tumors and rare malignancies. Oncolytic viruses represent a double antitumor strategy: they have an oncolytic activity and on top of that, they promote lymphocyte infiltration and immune responses against tumors. We are designing and evaluating new oncolytic adenovirus to improve their Intratumor diffusion and tumor reactivity and testing those using murine models. We are developing CAR-NK cells models, cell therapies based on autoreactive TCRs from patients and combined ATMP using virus and mesenchymal stem cells. We combine clinical and translational research, and we have led different clinical trials based on immunotherapy, demonstrating the feasibility of immunotherapy approaches to treat this kind of tumors.

Group members

Ramón Alemany Bonastre

Group leaders

Josep Maria Piulats Rodríguez

Group leaders

Publications

Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy

12 de July de 2018/in Alemany’s & Piulats’s lab/by

Cancer Res. 2018 Sep 1;78(17):4891-4901. doi: 10.1158/0008-5472.CAN-17-3754. Epub 2018 Jul 10. ABSTRACT Dogs with spontaneous tumors treated in veterinary hospitals offer an excellent opportunity for studying immunotherapies, including oncolytic viruses. Oncolytic viruses have advanced into the clinic as an intratumorally administered therapeutic; however, intravenous delivery has been hindered by neutralization in the blood. To circumvent […]

Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus

12 de June de 2018/in Alemany’s & Piulats’s lab/by

Mol Ther Oncolytics. 2018 Jan 31;8:62-70. doi: 10.1016/j.omto.2018.01.003. eCollection 2018 Mar 30. ABSTRACT To enhance adenovirus-mediated oncolysis, different approaches that tackle the selectivity, tumor penetration, and spreading potential of oncolytic adenoviruses have been reported. We have previously demonstrated that insertion of the internalizing Arginine-Glycine-Aspartic (iRGD) tumor-penetrating peptide at the C terminus of the fiber or […]

Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model

26 de May de 2018/in Alemany’s & Piulats’s lab/by

J Med Virol. 2018 Oct;90(10):1669-1673. doi: 10.1002/jmv.25229. Epub 2018 Jun 11. ABSTRACT Oncolytic adenoviral immunotherapy activates the innate immune system with subsequent induction of adaptive tumor-specific immune responses to fight cancer. Hence, oncolytic viruses do not only eradicate cancer cells by direct lysis, but also generate antitumor immune response, allowing for long-lasting cancer control and […]

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations

19 de April de 2018/in Alemany’s & Piulats’s lab/by

Clin Cancer Res. 2018 Aug 1;24(15):3717-3728. doi: 10.1158/1078-0432.CCR-17-3509. Epub 2018 Apr 17. ABSTRACT Purpose: Throughout their development, tumors are challenged by the immune system, and they acquire features to evade its surveillance. A systematic view of these traits, which shed light on how tumors respond to immunotherapies, is still lacking.Experimental Design: Here, we computed the […]

Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer

18 de April de 2018/in Alemany’s & Piulats’s lab/by

Oncotarget. 2018 Mar 23;9(22):15968-15983. doi: 10.18632/oncotarget.24641. eCollection 2018 Mar 23. ABSTRACT Individual and small clusters of cancer cells may detach from the edges of a main tumor and invade vessels, which can act as the origin of metastasis; however, the mechanism for this phenomenon is not well understood. Using cancer tissue-originated spheroids, we studied whether […]

Research Projects

Name: Dr Ramón Alemany Bonastre
Role: Group leader (coPI)

Name: Dr Josep Maria Piulats Rodríguez, MD
Role: Group leader (coPI)

Name: Dr Rafael Moreno Olié
Role: Principal Investigator

Name: Dr María Dolores López Robles
Role: Postdoctoral researcher

Name: Dr Marcel Costa García
Role: Postdoctoral Researcher

Name: Dr Gabriel Espinosa Carrasco
Role: Postdoctoral researcher

Name: Sílvia Torres Manjón
Role: Lab manager

Name: Laura Moya Borrrego
Role: Predoctoral Researcher

Name: Pau Fiol Mata
Role: Predoctoral Researcher

Name: Luís Paul del Carpio Huerta, MD
Role: Predoctoral Researcher (Rio Ortega contract)

Name: Juan Antonio Marín Jiménez, MD
Role: Predoctoral Researcher (La Caixa- Inphinit Retaining)

Name: Sebastián Ciro Carné Martín
Role: Predoctoral Researcher

Name: Ainhoa Muñoz Metrino
Role: Technician

Name: Dr Carles Codony Servat
Role: Project manager

Collaborations

Dr Alemany has published 129 articles, several book chapters and 16 patents (5 in the exploitation phase) in the field of therapeutic use of adenoviruses as gene vectors or oncolytic viruses. Editor of the journals “Gene Therapy” “Cancer Gene Therapy” and “Human Gene Therapy”, President of the Spanish Society of Gene and Cellular Therapy from 2016 to 2018, and advisor to several biotech companies that develop oncolytic viruses (ORCA Therapeutics, Oncolytics Biotech, Sagetis). In 2009 he co-founded the company VCN Biosciences. GHe collaborates among othersc with: Cristina Fillat Fonts, IDIBAPS; Juan José Rojas Expósito, IDIBELL; Javier García Castro, ISCIII , Madrid; Manuel Ramírez Orellana, Hosp Niño Jesús, Madrid; Alena Gros Vidal, VHIO; Sonia Guedan Carrió, IDIBAPS.

Dr Piulats is chair for Uveal Melanoma in the Spanish Melanoma group. He is part of the IRCI (International Rare Cancer Initiative) and EURACAN for rare melanoma and rare cutaneous tumors. He collaborates with Dr Alvaro Aytes (Idibell) and Dr Himisha Beltran (Dana Farber) in prostate cancer (projects Fundación Mútua Madrileña and DoD Prostate Cancer) and with Dr Xavier Matías-Guiu and Dr Alena Gros in Gynecologic tumors (La MaratóTV3, Immune4all in Ayudas de Proyectos de Investigación de Medicina Personalizada de Precisión). He collaborates with Dr Moreno (ICO-Idibell) and Dr África González Murillo (Hospital Universitario del Niño Jesús) in the PULSE-UM clinical study and with Dr Juan Marín Liberal (ICO), Drs Alena Gros, Elena Garralda (VHIO), Dr Sergi Querol (Banc de sang i Teixits) and Dr Jesús García-Donas Jiménez (Centro Integral Oncológico Clara Campal) (Proyectos Clinica Independiente – ISCIII).

Presently Dr Piulats has begun a collaboration asking for new funding for novel treatments in metastatic uveal melanoma with Alena Gros (VHIO), Gal Cafri and Yochai Wolf from Sheba Research Institute in Israel and Udai Kammula from UPMC in USA.

Dr Moreno collaborates in the development of NK-CAR cells with Dr Ana Sureda (ICO). He also collaborates with Dr. Marta Alonso (CIMA-University of Navarra) in the development towards a protocol and clinical application for GBM.

Cancer immunotherapy Alemany’s & Piulats’s lab

DESCRIPTION

Ramón Alemany Bonastre

Group leaders

Josep Maria Piulats Rodríguez

Group leaders

Rafael Moreno Olié

Researchers

María Dolores López Robles

Researchers

Gabriel Espinosa Carrasco

Researchers

Marcel Costa García

Researchers

Luís Paul del Carpio Huerta

Researchers

Juan Antonio Marín Jiménez

Young investigators

Laura Moya Borrego

Young investigators

Pau Fiol Mata

Young investigators

Sebastián Ciro Carné Martín

Young investigators

Silvia Torres Manjón

Support staff

Ainhoa Muñoz Metrino

Support staff

Carles Codony Servat

Support staff

CONTACT US

Cancer immunotherapy
Alemany’s & Piulats’s lab